Prognostic value of the BAP1 gene expression level in patients with clear cell renal cell carcinoma

Introduction. There is a lack of evidence of BAP1 expression on patient prognosis, that indicates the need for further study of this topic.

Aim. To evaluate BAP1 expression level in clear cell kidney cancer patients.

Materials and methods. We included in a retrospective study based on N.N. Blokhin National Medical Research Center of Oncology database from 2009 to 2013 patients with clear cell kidney cancer, who were divided into 2 groups depending on BAP1 status. Primary endpoints were BAP1 expression level, 5-year overall survival (OS), disease-free survival (DFS) and cancer-specific survival (CSS).

Results. 40 patients were included in the BAP1+ group, 53 patients – in the BAP1– group. There were no statistically significant differences in parameters that could affect the prognosis between our groups. 5-year OS was higher in the BAP1+ group (76.0 %) compared to BAP1– (58.0 %) (p = 0.040). There were no statistically significant differences between 5-year DFS and CSS.

Conclusions. BAP1+ patients had significantly higher OS, but BAP1 mutation didn’t affect DFS and CSS.